scholarly journals Sch 38519, a novel platelet aggregation inhibitor produced by a Thermomonospora sp. Taxonomy, fermentation, isolation, physico-chemical properties, structure and biological properties.

1989 ◽  
Vol 42 (7) ◽  
pp. 1063-1069 ◽  
Author(s):  
M. PATEL ◽  
V. HEGDE ◽  
A. HORAN ◽  
T. BARRETT ◽  
R. BISHOP ◽  
...  
2020 ◽  
Vol 27 (28) ◽  
pp. 4584-4592 ◽  
Author(s):  
Avik Khan ◽  
Baobin Wang ◽  
Yonghao Ni

Regenerative medicine represents an emerging multidisciplinary field that brings together engineering methods and complexity of life sciences into a unified fundamental understanding of structure-property relationship in micro/nano environment to develop the next generation of scaffolds and hydrogels to restore or improve tissue functions. Chitosan has several unique physico-chemical properties that make it a highly desirable polysaccharide for various applications such as, biomedical, food, nutraceutical, agriculture, packaging, coating, etc. However, the utilization of chitosan in regenerative medicine is often limited due to its inadequate mechanical, barrier and thermal properties. Cellulosic nanomaterials (CNs), owing to their exceptional mechanical strength, ease of chemical modification, biocompatibility and favorable interaction with chitosan, represent an attractive candidate for the fabrication of chitosan/ CNs scaffolds and hydrogels. The unique mechanical and biological properties of the chitosan/CNs bio-nanocomposite make them a material of choice for the development of next generation bio-scaffolds and hydrogels for regenerative medicine applications. In this review, we have summarized the preparation method, mechanical properties, morphology, cytotoxicity/ biocompatibility of chitosan/CNs nanocomposites for regenerative medicine applications, which comprises tissue engineering and wound dressing applications.


1988 ◽  
Vol 263 (36) ◽  
pp. 19827-19832 ◽  
Author(s):  
Z R Gan ◽  
R J Gould ◽  
J W Jacobs ◽  
P A Friedman ◽  
M A Polokoff

1988 ◽  
Vol 108 (6) ◽  
pp. 555-561 ◽  
Author(s):  
AKIRA NIWA ◽  
OSAMU TAKEDA ◽  
MASAKO ISHIMARU ◽  
YASUKO NAKAMOTO ◽  
KAZUO YAMASAKI ◽  
...  

1996 ◽  
Vol 48 (6) ◽  
pp. 573-577 ◽  
Author(s):  
THIERRY LAVE ◽  
ALPHONSE SANER ◽  
PHILIPPE COASSOLO ◽  
R. BRANDT ◽  
ANNE H. SCHMITT-HOFFMANN ◽  
...  

1990 ◽  
Vol 28 (5) ◽  
pp. 20-20

Platet 300 Cleartab (Nicholas) is an effervescent buffered aspirin formulation which the maker has described as “a new cardiovascular-specific presentation of aspirin “and” the only platelet aggregation inhibitor to be licensed for use following acute myocardial infarction, or in patients with unstable angina, to reduce the risk of infarction”.


Sign in / Sign up

Export Citation Format

Share Document